For instance, Yu et al. developed a nomogram incorporating Ki67 and additional biomarkers to assess recurrence risk in patients with luminal breast cancer over 50 years old, addressing the limitations faced by that ineligible for 21-gene testing (28). This evidence concerns the gene MKI67 and breast carcinoma.